Analysts Set Ventyx Biosciences, Inc. (NASDAQ:VTYX) PT at $15.50

Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) have been assigned a consensus rating of “Moderate Buy” from the five brokerages that are presently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating and four have given a buy rating to the company. The average 12-month price target among brokers that have covered the stock in the last year is $15.50.

Several research firms have commented on VTYX. Oppenheimer increased their target price on Ventyx Biosciences from $9.00 to $14.00 and gave the company an “outperform” rating in a research report on Monday, October 27th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Ventyx Biosciences in a report on Wednesday, October 8th. Canaccord Genuity Group boosted their target price on shares of Ventyx Biosciences from $14.00 to $16.00 and gave the stock a “buy” rating in a report on Friday, November 7th. HC Wainwright upgraded shares of Ventyx Biosciences from a “neutral” rating to a “buy” rating and set a $18.00 price target for the company in a research report on Wednesday, November 5th. Finally, Wells Fargo & Company lifted their price target on shares of Ventyx Biosciences from $11.00 to $14.00 and gave the stock an “overweight” rating in a report on Friday, November 7th.

Ventyx Biosciences Price Performance

Shares of NASDAQ:VTYX opened at $8.40 on Friday. Ventyx Biosciences has a one year low of $0.78 and a one year high of $10.55. The company has a market cap of $599.42 million, a price-to-earnings ratio of -5.60 and a beta of 1.23. The firm has a 50 day simple moving average of $8.85 and a 200 day simple moving average of $4.95.

Ventyx Biosciences (NASDAQ:VTYX) last posted its earnings results on Thursday, November 6th. The company reported ($0.32) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.13. As a group, analysts expect that Ventyx Biosciences will post -2.09 EPS for the current year.

Insider Activity

In other news, insider John Nuss sold 12,675 shares of the stock in a transaction dated Thursday, December 18th. The stock was sold at an average price of $7.72, for a total value of $97,851.00. Following the completion of the sale, the insider owned 489,481 shares of the company’s stock, valued at approximately $3,778,793.32. This represents a 2.52% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Raju Mohan sold 47,345 shares of Ventyx Biosciences stock in a transaction that occurred on Thursday, December 18th. The stock was sold at an average price of $7.72, for a total value of $365,503.40. Following the completion of the transaction, the chief executive officer directly owned 2,372,863 shares in the company, valued at approximately $18,318,502.36. This represents a 1.96% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 14.49% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in VTYX. Nuveen LLC bought a new stake in shares of Ventyx Biosciences in the 1st quarter valued at $194,000. Walleye Capital LLC lifted its holdings in Ventyx Biosciences by 5.5% in the first quarter. Walleye Capital LLC now owns 504,245 shares of the company’s stock valued at $580,000 after buying an additional 26,457 shares during the period. Ieq Capital LLC bought a new stake in Ventyx Biosciences during the first quarter valued at $223,000. Redmile Group LLC grew its holdings in Ventyx Biosciences by 1,164.1% during the 1st quarter. Redmile Group LLC now owns 1,569,793 shares of the company’s stock worth $1,805,000 after acquiring an additional 1,445,615 shares during the period. Finally, ADAR1 Capital Management LLC grew its holdings in Ventyx Biosciences by 126.1% during the 1st quarter. ADAR1 Capital Management LLC now owns 281,600 shares of the company’s stock worth $324,000 after acquiring an additional 157,070 shares during the period. Institutional investors own 97.88% of the company’s stock.

About Ventyx Biosciences

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome.